Loading company…
OncoHost develops precision oncology tests to inform cancer treatment decisions.
OncoHost's PROphet® platform analyzes patient samples to predict response to PD-1/PD-L1 inhibitors and support oncology treatment decisions. The company serves healthcare providers, oncologists and researchers across North America, Europe and Asia. Founded in 2017 in Israel, it received a EUR 2.5 mn Horizon Europe grant on May 15, 2025.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in